Rather than tumor size alone, the American Thyroid Association’s risk stratification system should be used when assessing ...

A new study led by researchers at Yale University published in Environmental Health Perspectives, suggests that early-life ...

“In patients with BCG-unresponsive bladder carcinoma in situ and papillary NMIBC treated with BCG and the novel agent [Anktiva], [complete responses] were achieved with a persistence of effect, ...

Specific genetic mutations can result in more aggressive cancer variants. Medical professionals may conduct tests to identify biomarkers associated with these mutations, helping to predict the ...

“What we’ve shown is that these variants don’t just sit in the background—they can play an active role in how tumors form, how they evolve, and even how they respond to treatment. This opens new ...

From that, the PRAC has concluded that the data “does not support a causal association” between the drugs and thyroid cancer and sees no need to update the product information at this time.

You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.